Farxiga vs. Glyxambi Berinert vs. Cinryze Emgality vs. Qulipta Farxiga vs. Invokana Firazyr vs. Sajazir Glyxambi vs. Invokana Invokamet vs. Synjardy Opzelura vs. Dupixent Orencia vs. Rinvoq Qulipta vs. Vyepti Stelara vs. Tremfya Synjardy vs. Victoza Taltz vs. Bimzelx Vyepti vs. Nurtec ODT View all Comparisons

ADHD drugs Anxiety drugs Asthma drugs Atopic dermatitis drugs Depression drugs Heart failure drugs Hypertension drugs Lymphoma drugs Osteoarthritis drugs Rheumatoid arthritis drugs Rosacea drugs Schizophrenia drugs Type 2 Diabetes drugs View all Indications

Bayer drugs AbbVie drugs AstraZeneca drugs Eli Lilly and Company drugs Genetech drugs GlaxoSmithKline (GSK) drugs Novartis drugs Pfizer drugs Takeda Pharmaceuticals drugs Teva Pharmaceuticals drugs Amgen drugs View all Manufacturers

Beta-Adrenergic Blocker Angiotensin Converting Enzyme Inhibitor Angiotensin 2 Receptor Blocker Calcium Channel Blocker Diuretics HMG-CoA Reductase Inhibitor Proton Pump Inhibitor Selective Serotonin Reuptake Inhibitor Norepinephrine Reuptake Inhibitor Benzodiazepines Opioid Agonists Nonsteroidal Anti-inflammatory Drugs Antiepileptic Agents Antipsychotics Antihistamines View all Classes

Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®

HIPAA COMPLIANT

Soc 2 Type II

HIPAA COMPLIANT

Soc 2 Type II

For ProvidersRequest Demo Join Research Panel

Prescribing toolsPrescribing Info Coverage Savings Patient Resources A-Z Indications Compare Drugs

CompanyAbout Careers Contact Us Security

Get the latest insights in your inbox

Terms and Conditions

© 2026 PrescriberPoint. All Rights Reserved.

View All Cystic Fibrosis Transmembrane Conductance Regulator Potentiator

Home
Class
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator

Cystic Fibrosis Transmembrane Conductance Regulator Potentiator class drugs

FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

2 results

orkambi
(lumacaftor and ivacaftor)
Medication Details
Vertex Pharmaceuticals Incorporated
Usage: ORKAMBI is indicated for the treatment of cystic fibrosis in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. Efficacy and safety have not been established in other CF genotypes. Testing for the mutation is recommended if unknown.
Medication Details
Drug Interactions
trikafta
(Elexacaftor, Tezacaftor, and Ivacaftor)
Medication Details
Vertex Pharmaceuticals Incorporated
Usage: TRIKAFTA is indicated for treating cystic fibrosis in patients aged 2 years and older with at least one F508del mutation in the CFTR gene, or other responsive CFTR mutations verified by clinical or laboratory data. An FDA-cleared CF mutation test is recommended if the genotype is unknown.
Medication Details
Drug Interactions